coagulation factor X ; Homo sapiens

76 Article(s)
Pub. Year
#Total Relationships
1 34655821 Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin. 2022 Jan 1
2 35100448 Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients. 2022 Mar 1
3 32888192 Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT. 2021 Jan 1
4 33400099 Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. 2021 Aug 1
5 33512867 Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. 2021 Oct 1 5
6 34078133 Safety and Efficacy of Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels in Pancreatic Surgery. 2021 Jun 2 2
7 34402789 Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80 mg/0.8 mL) subcutaneous injection in healthy adults. 2021 Nov 1
8 34733033 Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital. 2021 Aug 4
9 34781984 Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19. 2021 Nov 15 3
10 34884411 Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome-A Single Center Prospective Study. 2021 Dec 6 1
11 31463801 Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. 2020 Jan 1
12 31843692 Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients. 2020 Mar 1
13 31986476 Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients. 2020 Mar 1
14 32045583 Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. 2020 Jun 1
15 32391762 Early Anti-Xa Assay-Guided Low Molecular Weight Heparin Chemoprophylaxis Is Safe in Adult Patients with Acute Traumatic Brain Injury. 2020 Apr 1 1
16 32559127 Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study. 2020 Jan-Dec 2
17 32624425 Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. 2020 Oct 1
18 33086312 Low anti-Factor Xa level predicts 90-day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials. 2020 Oct 19 1
19 33155833 Which Trauma Patients Require Lower Enoxaparin Dosing for Venous Thromboembolism Prophylaxis? 2020 Oct 1
20 30698331 An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays. 2019 Jun 2
21 31112313 Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients. 2019 Jul 1
22 31116389 Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. 2019 Aug 1 1
23 28736059 Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose. 2018 Aug 1
24 29367044 Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose? 2018 Mar 2
25 29490713 Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. 2018 May 3
26 29626461 Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure. 2018 Aug 1
27 27936527 Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa. 2017 Feb 1
28 28467656 Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis. 2017 Jul 1
29 28808492 Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients. 2017 Jul-Sep 1
30 28846877 Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. 2017 Oct 2
31 28918992 Anti-factor Xa levels in patients undergoing laparoscopic sleeve gastrectomy: 2 different dosing regimens of enoxaparin. 2017 Oct 2
32 27256341 The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. 2016 Nov 1
33 27383732 Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. 2016 Nov 1 2
34 27440463 Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial. 2016 Sep 27 1
35 27693871 Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series. 2016 3
36 25325764 A practical approach to the use of low molecular weight heparins in VTE treatment and prophylaxis in children and newborns. 2015 Feb 1
37 25716128 Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study. 2015 Oct 1
38 24335994 IV enoxaparin in pediatric and cardiac ICU patients. 2014 Feb 1
39 24458050 Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. 2014 Feb 1
40 24943261 Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. 2014 Sep 1
41 25526009 Bullous hemorrhagic dermatosis distant from the site of heparin injection. 2014 Oct 15 1
42 23533746 The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. 2013 1
43 23808469 Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant. 2013 Jul 1
44 27121789 Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects. 2013 Jul 1
45 22565589 Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. 2012 Jul 3
46 22876779 Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. 2012 Sep 10 3
47 23227470 Bioactivity of enoxaparin in critically ill patients with normal renal function. 2012 Nov 3
48 20972772 Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. 2011 Jan 1
49 21083516 Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity. 2011 Jan 1
50 21150227 Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood. 2011 3